When is intravenous immunoglobulin (IVIG) indicated for acute transverse myelitis or multiple sclerosis, what is the recommended dosing schedule, and what safety considerations should be observed?

IVIG in Acute Transverse Myelitis and Multiple Sclerosis

IVIG is NOT a first-line treatment for acute transverse myelitis or multiple sclerosis relapses—high-dose intravenous corticosteroids remain the standard initial therapy. However, IVIG serves as a reasonable second-line option when steroids are contraindicated, ineffective, or in specific clinical scenarios requiring alternative immunotherapy.

Indications for IVIG

Acute Transverse Myelitis

• Second-line therapy when high-dose IV methylprednisolone fails to produce clinical improvement
• Alternative to steroids when corticosteroids are contraindicated or not preferred 1
• Consider IVIG first in agitated patients and those with bleeding disorders (where plasma exchange would be problematic) 1
• Limited evidence exists for IVIG monotherapy in transverse myelitis—one case report showed benefit in SLE-associated longitudinal extensive transverse myelitis 2, but a randomized controlled trial (STRIVE) failed to recruit adequately and could not determine efficacy 3

Multiple Sclerosis Relapses

• Alternative therapy when IV methylprednisolone is contraindicated or refused
• Research evidence suggests IVIG may reduce relapse frequency in relapsing-remitting MS, with one study showing 38.6% reduction in yearly exacerbation rate 4
• IVIG demonstrated non-inferiority to IV methylprednisolone in one small study for acute MS relapse treatment 5
• Not FDA-approved for MS—this represents off-label use based on limited evidence

Clinical Decision Algorithm

1. First-line: High-dose IV methylprednisolone (standard of care)
2. If no improvement after steroids: Add IVIG or plasma exchange 1
3. Choose IVIG over plasma exchange when:
   • Patient is agitated or uncooperative
   • Bleeding disorder present
   • Central line placement contraindicated
   • Plasma exchange not readily available
4. Choose plasma exchange over IVIG when:
   • Severe hyponatremia present
   • High thromboembolic risk (cancer, smoking, hypertension, diabetes, hyperlipidemia, hypercoagulable states)
   • Associated brain or spinal demyelination suggesting aggressive disease 1

Dosing Schedule

Acute Treatment Protocol

Standard regimen: 0.4 g/kg body weight daily for 5 consecutive days 6, 7

Infusion Rate (Critical for Safety)

• Initial rate: 0.01 mL/kg/minute (0.5 mg/kg/minute) 7
• If tolerated after 30 minutes: Gradually increase to maximum 0.10 mL/kg/minute (5 mg/kg/minute) 7
• Monitor vital signs continuously throughout infusion
• Slow or stop if adverse reactions occur; may resume at lower rate once symptoms resolve 7

Maintenance Therapy (if indicated)

• For relapsing-remitting MS: 0.4 g/kg every 6 weeks as booster doses 8
• For MOG-antibody disease: Monthly IVIG showed benefit in case reports 9
• Duration varies by condition and response—one case used monthly IVIG for 6 months in transverse myelitis 2

Safety Considerations

Major Risks (Black Box Warnings)

Thrombosis 7:

• Risk factors: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous/arterial thrombosis, estrogen use, indwelling central catheters, hyperviscosity, cardiovascular risk factors
• Can occur even without known risk factors
• Administer at minimum dose and infusion rate in at-risk patients
• Ensure adequate hydration before administration
• Monitor for thrombosis signs and assess blood viscosity in high-risk patients

Acute Renal Failure 7:

• Risk factors: pre-existing renal insufficiency (any degree), diabetes mellitus, age >65 years, volume depletion, sepsis, paraproteinemia, nephrotoxic drugs
• More common with sucrose-containing products (Flebogamma does NOT contain sucrose) 7
• Mandatory pre-hydration in all patients
• Use minimum effective dose and slowest infusion rate in at-risk patients

Common Adverse Effects

• Headache: Most common (12.6% during loading dose) 8
• Flushing, fever, chills, fatigue, nausea, diarrhea, blood pressure changes, tachycardia 10
• Annual adverse event rate decreases with continued treatment (4.4% first year, declining thereafter) 8
• Overall adverse event rate: 3% of infusions in large MS cohort 4

Contraindications

• Absolute: History of anaphylactic or severe systemic hypersensitivity to human immunoglobulin 7
• Absolute: IgA-deficient patients with anti-IgA antibodies and history of hypersensitivity 7

Critical Safety Measures

1. Hydration protocol: Ensure adequate hydration before and during infusion 7, 10
2. Slow infusion rate: Start at 0.01 mL/kg/minute, increase gradually only if tolerated 7, 10
3. Separate IV line: Do not mix with other medications or fluids 7
4. Monitor continuously: Vital signs throughout infusion 7
5. Risk stratification: Identify patients with thrombotic or renal risk factors before treatment 7

Administration Pitfalls to Avoid

• Never dilute IVIG with IV fluids 7
• Never mix different IVIG formulations or manufacturers 7
• Never use partially used vials (no preservative) 7
• Never use frozen solution 7
• Inspect for particulate matter and turbidity before use 7

Evidence Quality Assessment

The evidence for IVIG in these conditions is limited and mixed:

• Transverse myelitis: Primarily case reports and one failed RCT 2, 3—evidence is weak
• MS relapses: Small studies showing potential benefit 5, 4, but not FDA-approved and not guideline-recommended as first-line
• Autoimmune encephalitis guidelines 1 provide the strongest framework, suggesting IVIG as alternative or add-on to steroids, but these are for encephalitis, not specifically myelitis or MS

The 2021 autoimmune encephalitis guidelines 1 provide the most robust framework for decision-making, though they address a related but distinct condition. The principle of using IVIG as second-line or alternative therapy when steroids fail or are contraindicated appears reasonable to extrapolate to transverse myelitis and MS relapses, given the shared autoimmune pathophysiology.